| Literature DB >> 31246685 |
Romain Schollhammer1, Henri de Clermont Gallerande1, Grégoire Robert2, Mokrane Yacoub3, Delphine Vimont1, Elif Hindié1, Philippe Fernandez1, Clément Morgat1.
Abstract
Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, Ga-prostate-specific membrane antigen-617 PET/CT, Ga-RM2 PET/CT, and F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31246685 DOI： 10.1097/RLU.0000000000002672
Source DB: PubMed Journal: Clin Nucl Med ISSN： 0363-9762 Impact factor: 7.794